The Efficiency of Modified Temozolomide in Glioblastoma Cell Death
School Name
Governor's School for Science and Mathematics
Grade Level
12th Grade
Presentation Topic
Physiology and Health
Presentation Type
Mentored
Abstract
Glioblastomas are a neurological disease and its standard treatment is the chemotherapeutic drug, Temozolomide [TMZ]. However, the use of TMZ only prolongs the one-year survival rate by 6-10%. One way to increase the efficiency of TMZ is to modify the chemical structure. The aim of this research is to modify TMZ by either adding an Ester group [TMZ-E] or a carboxylic acid [TMZ-A] to the chemical structure. And to test these modified drugs along with unmodified TMZ on an oligodendrocyte cell line, LN-229. The cells were treated at a concentration of 0-50 μM for twenty-four hours, followed by a trypan blue assay to determine cell death. The results indicate that TMZ-E was more effective at killing glioblastoma cells than TMZ and TMZ-A. At 0.8 μM TMZ-E killed about 67.4% of the cancerous cells as to compared to unmodified TMZ which killed 30%. These various TMZs will also be tested on other cancer cell lines.
Recommended Citation
Ramos Mendoza, Daniela, "The Efficiency of Modified Temozolomide in Glioblastoma Cell Death" (2018). South Carolina Junior Academy of Science. 85.
https://scholarexchange.furman.edu/scjas/2018/all/85
Location
Neville 322
Start Date
4-14-2018 11:30 AM
Presentation Format
Oral and Written
The Efficiency of Modified Temozolomide in Glioblastoma Cell Death
Neville 322
Glioblastomas are a neurological disease and its standard treatment is the chemotherapeutic drug, Temozolomide [TMZ]. However, the use of TMZ only prolongs the one-year survival rate by 6-10%. One way to increase the efficiency of TMZ is to modify the chemical structure. The aim of this research is to modify TMZ by either adding an Ester group [TMZ-E] or a carboxylic acid [TMZ-A] to the chemical structure. And to test these modified drugs along with unmodified TMZ on an oligodendrocyte cell line, LN-229. The cells were treated at a concentration of 0-50 μM for twenty-four hours, followed by a trypan blue assay to determine cell death. The results indicate that TMZ-E was more effective at killing glioblastoma cells than TMZ and TMZ-A. At 0.8 μM TMZ-E killed about 67.4% of the cancerous cells as to compared to unmodified TMZ which killed 30%. These various TMZs will also be tested on other cancer cell lines.
